The current most-used biomarker for HCC screening is serum alpha fetoprotein (AFP), which has been shown to possess limited sensitivity (~40–60%)4 at the cutoff of 20 ng/mL recommended by American Association for the Study of Liver Diseases (AASLD)5. This evidence concerns the gene AFP and hepatocellular carcinoma.